Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 4/20 | 0.47 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 2/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2781359 | 0.85 | DPP4 (0.55) | SCN4ADPP4F2HRH1GRIN2D | |
| SCHEMBL2784864 | 0.85 | DPP4 (0.55) | SCN4ADPP4F2HRH1GRIN2D | |
| SCHEMBL2781356 | 0.85 | DPP4 (0.55) | SCN4ADPP4F2HRH1GRIN2D | |
| SCHEMBL27945427 | 0.80 | SCN4A (0.50) | SCN4ADPP4F2GRIN2DGRIN3B | |
| SCHEMBL4672036 | 0.80 | HRH1 (0.68) | SCN4ADPP4F2HRH1HTR2A | |
| SCHEMBL27866703 | 0.80 | SCN4A (0.50) | SCN4ADPP4F2GRIN2DGRIN3B | |
| SCHEMBL4672537 | 0.80 | HRH1 (0.68) | SCN4ADPP4F2HRH1HTR2A | |
| SCHEMBL4679643 | 0.80 | HRH1 (0.68) | SCN4ADPP4F2HRH1HTR2A | |
| SCHEMBL17373052 | 0.80 | SCN4A (0.50) | SCN4ADPP4F2HRH1GRIN2D | |
| Bromide SCHEMBL28853590 | 0.78 | HRH1 (0.65) | SCN4ADPP4F2HRH1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376124-A2 | SMART CONTRAST AGENTS FOR MRI IMAGING | Universite de Rouen (FR) | 2011-10-19 | — | — | EP | disclosed |
| US-20110243857-A1 | SMART CONTRAST AGENTS FOR MRI IMAGING | UNIVERSITE DE ROUEN (FR) | 2011-10-06 | — | — | US | disclosed |
| WO-2010070126-A2 | SMART CONTRAST AGENTS FOR MRI IMAGING | UNIVERSITE DE ROUEN (FR) | 2010-06-24 | — | — | WO | disclosed |
| WO-2005061462-A2 | DIARYL PYRAZOLE DERIVATIVES AND THEIR USE AS NEUROKININ-3 RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110243857-A1 | SMART CONTRAST AGENTS FOR MRI IMAGING | CALCOCO2, COIL, CDR2 | SCN4A 1187/4885DPP4 2549/4885F2 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.